<DOC>
	<DOCNO>NCT03046693</DOCNO>
	<brief_summary>Clinical trial.gov Brief summary : Non-arteritic anterior ischemic optic neuropathy ( NAION ) optic neuropathy due acute subacute ischemic event anterior optic nerve axon retrolaminar part vascularize posterior ciliary brevis artery . The incidence ischemia follow axonal edema cause compartment syndrome heighten incidence ischemic . In NAION , main pathology occur level optical nerve , axon retinal ganglion cell . Initial damage optic disc ischemia result hypoxic injury axon manifest disc edema . Axonal edema cause disturbance retrograde axonal transport neurotrophic factor , especially brain derived neurotrophic factor , retinal ganglion cell . This trigger secondary toxicity apoptosis . In addition , presence oxidative stress , calcium influx mitochondrial damage also trigger apoptosis . After apoptosis retinal ganglion cell , thin retinal nerve fiber layer ( RNFL ) Wallerian degeneration . Thinning RNFL manifest visual field defect decline visual acuity patient chronic phase NAION . Though NAION include disease entity long exist , , evidence-based study medical surgical procedure effective enough overcome NAION . The main treatment manage risk factor hypertension , dyslipidemia , diabetes mellitus , hypercoagulable state . In general , patient acute phase ( edema optic nerve head ) , methylprednisolone administration may consider , patient already chronic phase ( atrophy disc ) generally occur 6-11 week onset , steroid longer indicate . Neuroprotective agent consider treatment NAION give primary pathology NAION retinal ganglion cell axon . Among various neuroprotective substance , Citidine diphosphocoline ( CDP-choline 5'-diphosphocholine Citicoline ) therapeutic option NAION . Citicoline endogenous mononucleotide consist ribose , cytosine , pyrophosphate , choline . Citicoline component intermediate synthesis phospholipid cell membrane , ie phosphatidylcholine . Exogenous citicoline administer orally intravenously , split citidine choline . Citicoline via oral administration absorb completely similar bioavailability blood compare parenteral administration intravenous . Once absorb , citicoline distribute throughout body enter blood-brain barrier blood retinal barrier penetrate central nervous system . If damage neuron , exogenous citicoline participate synthesis phospholipid neuronal cell membrane . Some study show citicoline may neuroprotective effect retinal ganglion cell support regeneration damage neuron vitro . Previous research citicoline effect chronic phase NAION give satisfactory result . Dopaminergic neurotransmitter system know occur vast number retina post-retinal visual pathway . Retinal ganglion cell use certain subtypes dopamine mean communication visual cortex . Rejdak et al animal model show citicoline administration could improve strengthen dopamine transmission retina . Citicoline also safe medicine , without serious adverse effect . Electroretinogram ( ERG ) tool measure function retina . ERG examination measure electrical change retina light stimulus . ERG examination detect change activity retinal ganglion cell pattern ERG . Spectral-domain optical coherence tomography tool measure thickness retinal ganglion cell . Thinning RNFL manifest visual field defect patient NAION . The typical visual field defect NAION altitudinal defect associate segmental edema optic nerve head . Based description question arise whether citicoline supplementation repair damage neuron retina , especially retinal ganglion cell , NAION result improved retinal function judge improvement value amplitude wave P50 N95 examination pattern ERG ( PERG ) compare placebo ? In addition whether citicoline supplementation increase thickness retinal ganglion cell assess use SD-OCT ? Does citicoline supplementation give effect improve visual field defect patient NAION ?</brief_summary>
	<brief_title>Citicoline Effect Non-arteritic Anterior Ischemic Optic Neuropathy ( NAION )</brief_title>
	<detailed_description>Research design This study double blind randomize clinical trial determine difference wave amplitude P50 N95 pattern ERG examination , visual field defect ( LP ) Humphrey HFA ( Humphrey Field Analyzer ) II-i 750 , 24-2 threshold ganglion cell thickness OCT CirrusTM administration citicoline placebo patient non-arteritic anterior ischemic optic neuropathy ( NAION ) chronic phase . Masking applied patient researcher . Research Time Place This research conduct Eye Clinic Division Neuro-Ophthalmology Faculty medicine Universitas Indonesia- RSCM ( Cipto Mangunkusumo Hospital ) Kirana ( single centre ) , Jakarta , Indonesia November 2016-June 2017 . Population Sample Research The target population study patient chronic phase NAION . Samples select consecutive sampling method , ie NAION patient chronic phase come Faculty medicine Universitas Indonesia-RSCM Kirana Neuro-ophthalmology division fulfil inclusion criterion include study randomize researcher . If patient NAION acute phase , visit become chronic phase meet inclusion criterion , patient sample . Inclusion criteria 1 . Patients age 20-65 year . 2 . NAION patient diagnose clinically minimum 1 consultant Division NO onset ≥6 week . 3 . Best correct visual acuity ≥ 1/60 Snellen 4 . Patients get explanation purpose research procedure undertake willing participate study signing inform consent . 5 . On bilateral NAION , examination research do one eye nearby onset 6 week Exclusion criterion 1 . Haziness refractive medium , corneal opacity opacities lens moderate severe ( color turbidity lens , cortex posterior capsule degree LOCs ( Lens Opacity Classification System ) III &gt; 3 ) . 2 . Abnormalities macula optic disc due cause NAION . 3 . Patients history glaucoma . 4 . Patients intraocular inflammation anterior posterior uveitis . 5 . Taking antioxidant supplement neuroprotective agent last 2 week randomization . 6 . Edema optic nerve head condition detect clinically OCT . Dropout Criteria 1 . Patients study drug administration period experience NAION contralateral eye require steroid therapy . 2 . Patients experience severe side effect ( headache , nausea , vomit ) resolve symptomatic medication . Sample calculation The sample size calculate base previous study measure amplitude wave N95 PERG patient NAION . From previous study obtain standard deviation 55 % . The researcher set value minimal clinical difference consider significant 0.55 . The sample size study calculate base formula sample test numerical analytic unpaired . Sample size 16 people per group . Taking account drop rate 20 % , set take sample 20 people treatment group ( Group A : citicoline group B : placebo ) Subject allocation Subjects fulfil inclusion exclusion criterion study ask sign inform consent randomization . The allocation subject do use block randomization . Randomization perform third party study begin . Number randomization result incorporate white envelope seal classify group A ( got citicoline ) group B ( placebo ) accordance result randomization . Examination Intervention 1 . History taking , obtain basic data patient 's identity , course disease time , history previous disease ( systemic ocular ) , history previous treatment . 2 . Ophthalmological examination perform include : 1 . Examination visual acuity use Snellen chart patient read use Illiterate E chart patient read . Examination visual acuity conduct refractionist Department Ophthalmology Faculty medicine Universitas Indonesia-RSCM Kirana . 2 . Complete ophthalmological examination use slit lamp conduct residence Division Neuro-ophthalmology . 3 . Examination eye pressure use non-contact tonometry ( NCT ) . 4 . Fundus examination fundus photograph operator . 3 . Patients meet inclusion criterion study offer follow study . Researchers explain purpose procedure study , use give drug , possible side effect drug give . Patients willing follow study ask sign inform consent . 4 . Subjects randomize group A ( citicoline ) group B ( placebo ) . 5 . Examination visual field use Humphrey HFA II-i 750 , 24-2 threshold anterior operator certify . 6 . Examination retinal ganglion cell thickness use OCT Cirrus TM ( Trade Mark ) posterior operator certify . 7 . Examination pattern ERG investigator , accompany expert consultant Eye Clinic Division Neuro-ophthalmology follow standard International Society Clinical electrophysiology Vision ( ISCEV ) 1 . Before examination , eye drop local anesthetic eye drop ( pantocaine® ) eyelid forehead area clean abrasive paste give conductive paste . 2 . Fiber electrodes place top edge eyelid inferior border nasal canthus area , reference electrode skin area ipsilateral lateral canthus eyelid ground electrode forehead . 3 . Standard stimulus parameter set size box 0.80 , luminance 80 cd / m2 , contrast 100 % reversal rate 4 rev / s. 4 . Patients ask put head head rest fixation letter X middle screen recommend much flash . 5 . Examination start complete within 3-4 minute obtain minimum 100 free wave artifact . 6 . After completion examination , patient 's eye drop antibiotic eye drop ( C. Polygran® ) . 8 . Intervention : Subjects group A get citicoline 1000 mg per day 60 day subject group B get placebo 60 day ( citicoline placebo repackage pharmacist ) . 9 . During study , subject continue take systemic drug anti-hypertensive , anti-dyslipidemia , anti-diabetes , anti-coagulants usual ( control risk factor ) take multivitamin . 10 . To ensure patient take drug regularly study , researcher provide medication logbook ask patient provide check mark take drug every day . Patients ask consume drug morning breakfast minimum 60 minute consumption drug ( ) . Researchers also call patient week ensure patient take study drug regular basis . 11 . Patients require control 30 day drug usage examination visual acuity , complete ophthalmologic examination , Humphrey visual field examination , PERG examination thickness retinal ganglion cell SD-OCT . Evaluation logbook note complaint related side effect due intervention also assess follow . 12 . After 60 day intervention , re-examination include : visual acuity , complete ophthalmologic examination , Humphrey visual field examination , PERG examination thickness retinal ganglion cell use SD-OCT also note complaint related side effect result intervention assess final follow . 13 . The interpretation result PERG perform two expert consultant Neuro-Ophthalmology Division ( MS SN ) . Reporting Drug 's Side Effects From previous study , serious side effect report due use drug . In case unwanted side effect headaches gastrointestinal intolerance , researcher ask patient come clinic Faculty medicine Universitas Indonesia-RSCM Kirana give handle accord patient 's condition researcher decide whether patient still able continue research . The cost treatment side effect bear researcher . Researchers also ask patient fill form side effect drug . Operational definition 1 . Diagnosis NAION establish base follow criterion : sudden decrease visual acuity , optic disc edema atrophy optic nerve head funduscopy , find relative afferent pupillary defect ( unilateral ) , visual field abnormality ( LP ) consistent NAION . The diagnosis NAION confirm ophtalomologist charge Neuro-ophthalmology Policlinic Faculty medicine Universitas Indonesia-RSCM Kirana . The acute phase onset &lt; 6 week find edema optic nerve head fundoscopy thicken Retinal Nerve Fiber Layer ( RNFL ) basis least one quadrant optic nerve head OCT . Chronic phase ≥ 6 week onset found atrophy normal optic nerve head funduscopy RNFL thin basis least one quadrant optic nerve head OCT. 2 . Age : calculate base year research reduction birth year research subject . 3 . Onset : calculate base first time patient sign consent form participate study time minus typical complaint NAION start happen . 4 . Best correct visual acuity : result visual acuity use Snellen maximum refraction correction chart . Visual acuity correction convert logMar 5 . Diabetes Mellitus ( DM ) : The laboratory result blood fast blood sugar ≥ 126 mg / dL random blood glucose 2-hour post-prandial ≥ 200 mg / dL classical symptom HbA1c ≥ 6.5 % control DM hypoglycemic drug . 6 . Hypertension : Results measurement blood pressure ≥ 140/90 mmHg people hypertension control antihypertensive medication . 7 . Dyslipidemia : Results laboratory blood total cholesterol ≥ 200 mg / dL LDL ≥ 100 mg / dL HDL ≤ 50 mg / dL triglyceride level ≥ 100 mg / dL person dyslipidemia control dyslipidemia drug . 8 . Hypercoagulability : blood lab result Ivy bleed time &lt; 6 minute prothrombin time &gt; 11.2 second activate partial thromboplastin time &gt; 47 second fibrinogen level &gt; 384 mg / dL quantitative D-dimer &gt; 300 g / dL 1 μM platelet aggregation &gt; 15 % 5 μM platelet aggregation &gt; 68 % 10 μM platelet aggregation &gt; 84 % . 9 . Visual field visual field test result use Humphrey HFA II-i 750 , 24-2 threshold . Examination repeat take account confidence index meet three criterion : 1 . Fixation loss ≤ 20 % 2 . False positive ≤ 15 % 3 . False negative ≤ 20-30 % The parameter assess : 1 . The mean deviation ( MD ) : result average sensitivity retina patient compare normal population . This figure obtain total deviation . 2 . Pattern standard deviation ( PSD ) : result average sensitivity retina patient adapt show localized area index . This figure obtain pattern deviation . 10 . The thickness retinal ganglion cell anatomical cross-sectional examination retinal ganglion cell use optical coherence tomography ( OCT ) Cirrus TM HD ( High Definition ) -OCT 5000 . The mode panomap ganglion cell analysis : Macular Cube 512x128 200x200 cube Optic disc . Examination repeat minimal attention signal strength ≥ 5 . 11 . PERG examination : 1 . P50 wave amplitude amplitude measure valley N35 peak P50 . The unit use μV . 2 . N95 wave amplitude amplitude measure peak P50 valley N95 . The unit use μV . 3 . P50 wave implicit time time measure light stimulus crest wave P50 . The unit use ms. 4 . N95 wave implicit time time measure light stimulus crest wave N95 . The unit use ms. 5 . Latency time occurrence wave response . 12 . Side effect : systemic ocular complaint least 2 hour study drug consumption . Side effect report previously headache gastrointestinal intolerance . Research Ethics Once proposal approve research supervisor research coordinator Head Department Ophthalmology Faculty medicine Universitas Indonesia-RSCM Kirana , proposal submit Health Research Ethics Committee Faculty medicine Universitas Indonesia-RSCM review . The study begin study pass test ethic obtain number research protocols meet Declaration Helsinki register ClinicalTrials.gov website . Data analysis Data study record incorporated primary table , process SPSS ( Statistical Package Social Science ) version 17.0 . The analysis intention treat . If violation protocol incidence severe side-effects provide intervention stop lose follow-up least second measurement do ( 30 day ) , subject consider failure still include analysis . Patients also say drop administration intervention patient symptoms NAION contralateral eye require steroid therapy still include analysis carry least second measurement do ( 30 day ) . Data present form table graph . Data test whether distribution spread evenly normality test . Data analyze compare two average pair use unpaired t-test Mann Whitney test . Categorical data present form proportion . Statistical test difference proportion two independent group use chi-square test . Statistical test determine correlation use Pearson Spearman test .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Optic Nerve Diseases</mesh_term>
	<mesh_term>Optic Neuropathy , Ischemic</mesh_term>
	<mesh_term>Cytidine Diphosphate Choline</mesh_term>
	<criteria>1 . Patients aged 2065 year . 2 . NAION patient diagnose clinically minimum 1 consultant Division NO onset ≥6 week . 3 . Best correct visual acuity ≥ 1/60 Snellen 4 . Patients get explanation purpose research procedure undertake willing participate study signing inform consent . 5 . On bilateral NAION , examination research do one eye nearby onset 6 week 1 . Haziness refractive medium , corneal opacity opacities lens moderate severe ( color turbidity lens , cortex posterior capsule degree LOCs III &gt; 3 ) . 2 . Abnormalities macula optic disc due cause NAION . 3 . Patients history glaucoma . 4 . Patients intraocular inflammation anterior posterior uveitis . 5 . Taking antioxidant supplement neuroprotective agent last 2 week randomization . 6 . Edema optic nerve head condition detect clinically OCT .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Non-arteritic anterior ischemic optic neuropathy</keyword>
	<keyword>pattern electroretinography</keyword>
	<keyword>citicoline</keyword>
	<keyword>retinal ganglion cell</keyword>
	<keyword>visual field</keyword>
</DOC>